
We report a phase I study of the biological effects, zzso and zzso of 6- and 24-hour zzso infusions of zzso zzso zzso in cancer zzso zzso patients received the zzso zzso infusion regimen at doses ranging from zzso to zzso zzso zzso patients received the 24-hour zzso infusion regimen at doses ranging from zzso to zzso zzso zzso and zzso symptoms were the most common side effects and were seen at all dose zzso The maximum tolerated dose was zzso zzso for the zzso regimen and zzso zzso for the 24-hour zzso A zzso zzso was observed at doses greater than or equal to zzso zzso A marked increase in zzso zzso occurred by Day 5 of treatment in almost all patients, regardless of the dose zzso zzso serum levels of zzso were achieved only at doses of zzso zzso of the zzso zzso The mean serum zzso at this dose ranged from 18 to 83 zzso as measured by zzso zzso zzso by zzso zzso zzso against zzso did not develop in any zzso During the short period of evaluation of this study, one patient with zzso cell zzso achieved a partial response, and three patients with zzso cell zzso and lung zzso zzso respectively, achieved minor zzso This study will form the framework for phase II efficacy trials of zzso zzso 

